Hygieia Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Hygieia is a clinical-stage biopharmaceutical company focusing on RNAi product development with self-proprietary siRNA delivery platforms, targeting disease areas in CVM, CNS, autoimmune diseases, etc.
MVIP: BIC GalNAc platform, outstanding delivery efficiency and duration with proof of clinical PoC validation
Clinical-stage Assets: 1) Kylo-0603 (THRβ): phase 2 ready; 2) Kylo-11 (LPA-siRNA): phase 1 (phase 2 in 2025H2); 3) Kylo-12 (APOC3-siRNA): phase 1 ongoing
Global Collaborations available for both assets and platforms
Address
ShanghaiChina
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}